癌症生存者心房颤动射频导管消融安全性评估

Safety evaluation of radiofrequency catheter ablation for atrial fibrillation in tumor survivors

目的探讨既往有肿瘤病史的非瓣膜性心房颤动(简称房颤)患者进行射频导管消融治疗的安全性。方法收集269例行射频消融的房颤患者的临床资料,将其中有肿瘤病史的非瓣膜性房颤患者(共16例)作为肿瘤组,以无肿瘤病史的患者为非肿瘤组(共253例)。比较两组患者临床特点、围手术期并发症发生率等。结果肿瘤组中既往肿瘤主要为消化系统肿瘤(37.50%)、妇科肿瘤(25.00%)和呼吸系统肿瘤(18.75%)。围手术期两组并发症的发生率比较,差异无统计学意义;随访12个月房颤复发率差异也无统计学意义。结论有肿瘤病史的非瓣膜性房颤患者导管消融围手术期并发症发生率及术后复发率与无肿瘤病史者相当,射频消融可作为该类患者的治疗选择。

Objective To explore the safety of radiofrequency catheter ablation in patients with atrial fibrillation(AF)and a history of tumor.Methods We collected the clinical data of 269 AF patients who had undergone radiofrequency ablation.Among the enrolled patients,those non-valvular AF patients with a history of tumor were labeled as the tumor group(16 cases)while those without a history of tumor were divided into the non-tumor group(253 cases).The clinical characteristics and incidences of peripheral complications were compared between the two groups.Results The top three previous tumors are separately gastrointestinal tract tumor(37.50%),gynecology tumor(25.00%),and lung tumor(18.75%).There is no significant difference in the incidence of peripheral complications between the two groups.During 12-month follow-up,the recurrence rate of AF between the two groups also does not vary significantly.Conclusion In AF patients with a history of tumor,the incidence of complications during perioperative period of catheter ablation is similar to that of AF patients without tumor history,so is the postoperative recurrence rate of AF.Radiofrequency ablation could be used as one of the treatment options for such patients.